Duncan Williams

Duncan Williams is out with its report today on Forest Laboratories (NYSE: FRX), maintaining Buy. In a note to clients, Duncan Williams writes, "(1) We think the marketed portfolio is worth $28 per share and conservatively allocate $7 to the pipeline, with $10/share in cash. (2) The company has an...

Duncan Williams reiterated its Strong Buy rating on Noble (NYSE: NE). At the same time, the rating agency decided to leave its price target on the company's stock unchanged t $61.50. On Wednesday, NE added 0.77% to its value to finish the day at $36.42. Its shares continued to climb in today's pre-...

Duncan Williams reiterated its Strong Buy rating on Transocean (NYSE: RIG). At the same time, the rating agency left its price target on the company's stock unchanged at $101.25. On Wednesday, RIG added 1.12% to its value to end the day at $60.53. Its shares continued to climb in today's pre-market...

Duncan Williams maintained its Cadence Pharmaceuticals (NASDAQ: CADX) Strong Buy rating and $14 price target in a research report published today. In the report, Duncan Williams states, "We have not yet seen any weakness in the vial sales and formulary approvals have exceeded our expectations."...

Duncan Williams reiterated its Noble (NYSE: NE) Strong Buy rating and $61.50 price target in a research report published today. In the report, Duncan Williams states, "Noble's fleet status indicates some revival in the jackup market as new contracts have been signed in the North Sea. The last...

Duncan Williams reiterated its Atwood Oceanics (NYSE: ATW) Strong Buy rating and $60.75 price target in a research report published today. In the report, Duncan Williams states, "Atwood's fleet status had no new contracts, however, the Atwood Aurora has completed its enhancements in Italy. We have...

Duncan Williams maintained its Medicis Pharmaceutical (NYSE: MRX) Buy rating and $43 price target in a research report published today. In the report, Duncan Williams states, "(1) Medicis plans to initiate new marketing initiatives on Solodyn and Dysport in 3Q11 which are expected to drive...

Duncan Williams reiterated its Strong Buy rating on Willbros (NYSE: WB). At the same time, the rating agency left its price target on the company's stock unchanged at $16. On Monday, Willbros added 0.26% to its value to close the day at $7.67.

Duncan Williams has upgraded Rowan Companies (NYSE: RDC) from Buy to Strong Buy and has raised the price target from $46.50 to $50.25.

Duncan Williams has raised the price target on Forest Laboratories (NYSE: FRX) from $40 to $45 and maintains its Buy rating.

Duncan Williams maintained its Nabors Industries (NYSE: NBR) Buy rating and $37.50 price target in a research report published today. In the report, Duncan Williams states, "The company indicated weather delays in the Bakken and Marcellus areas had lowered revenues as well as late deliveries for...

Duncan Williams maintained its Obagi Medical Products (NASDAQ: OMPI) Hold rating in a research report published today. In the report, Duncan Williams states, "We are still not certain if the Texas issue is isolated or the beginning of more HQ caution (as we noted for internet retailers)." Shares...

Duncan Williams has raised the price target on Noble Corporation (NYSE: NE) from $54 to $61.50 and maintains its Strong Buy rating.

Duncan-Williams upgraded its rating on Diamond Offshore Drilling (NYSE: DO) from Neutral to Buy. The new price target was set to $86.25. In a research report published today, Duncan-Williams underlined better than expected Q1 results as a reason for this upgrade. In the report, Duncan-Williams...

Duncan Williams has upgraded Atwood Oceanics (NYSE: ATW) from Reduce to Strong Buy and has established a $60.75 price target.